A European multicentre, randomised study of the MAR-Tyn cobalt chromium tin-coated stent in patients with de novo coronary artery lesions

Study design and protocol

Adnan Kastrati, Marco Balducelli, Germano Di Sciascio, Tiziano Moccetti, Alessandro S. Bortone, Antonio Colombo, Johannes Waltenberger, Christoph Hehrlein

Research output: Contribution to journalArticle

Abstract

Aims: The aim of this randomised study is to evaluate the efficacy and safety of a new bare metal stents (BMS) with thin struts and a novel passive coating as compared to current standard BMS. Methods and results: We designed an international, multicentre, randomised trial planned to include 160 patients assigned to receive either the titanium-nitride coated MAR-tyn stent (International Biomedical Systems, Trieste, Italy) or the Vision stent (Abbott Vascular, Abbott Laboratories, Abbott Park, IL, USA). Patients with left main or bypass graft disease, complex coronary lesions, needing treatment of multiple lesions, with recent myocardial infarction, prior BMS in or within 5 mm of the target lesion, left ventricular ejection fraction ≤25% and at increased bleeding risk are excluded. All patients are treated with dual antiplatelet therapy for two months. The primary endpoint is in-stent late luminal loss (LL) at 6-month follow-up angiography. Secondary endpoints are the incidence of major adverse cardiovascular events (MACE) and stent thrombosis over 12 months after randomisation. Patients' enrolment is open in all centres. Conclusions: This study will address the important question of safety and efficacy of a novel, inert and highly compatible passive coating on a thin-strut BMS with a great potential to be superior to a non-coated widely used BMS.

Original languageEnglish
Pages (from-to)976-980
Number of pages5
JournalEuroIntervention
Volume5
Issue number8
DOIs
Publication statusPublished - Apr 2010

Fingerprint

Tin
Chromium
Cobalt
Multicenter Studies
Stents
Coronary Vessels
Metals
Safety
Random Allocation
Stroke Volume
Italy
Coronary Disease
Blood Vessels
Angiography
Thrombosis
Myocardial Infarction
Hemorrhage
Transplants
Incidence
Therapeutics

Keywords

  • Cobalt chromium stent
  • Coronary artery disease
  • Restenosis
  • Stent
  • Study design

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

A European multicentre, randomised study of the MAR-Tyn cobalt chromium tin-coated stent in patients with de novo coronary artery lesions : Study design and protocol. / Kastrati, Adnan; Balducelli, Marco; Di Sciascio, Germano; Moccetti, Tiziano; Bortone, Alessandro S.; Colombo, Antonio; Waltenberger, Johannes; Hehrlein, Christoph.

In: EuroIntervention, Vol. 5, No. 8, 04.2010, p. 976-980.

Research output: Contribution to journalArticle

Kastrati, A, Balducelli, M, Di Sciascio, G, Moccetti, T, Bortone, AS, Colombo, A, Waltenberger, J & Hehrlein, C 2010, 'A European multicentre, randomised study of the MAR-Tyn cobalt chromium tin-coated stent in patients with de novo coronary artery lesions: Study design and protocol', EuroIntervention, vol. 5, no. 8, pp. 976-980. https://doi.org/10.4244/EIJV5I8A163
Kastrati, Adnan ; Balducelli, Marco ; Di Sciascio, Germano ; Moccetti, Tiziano ; Bortone, Alessandro S. ; Colombo, Antonio ; Waltenberger, Johannes ; Hehrlein, Christoph. / A European multicentre, randomised study of the MAR-Tyn cobalt chromium tin-coated stent in patients with de novo coronary artery lesions : Study design and protocol. In: EuroIntervention. 2010 ; Vol. 5, No. 8. pp. 976-980.
@article{c0939de4219642fd89836b2877b5c002,
title = "A European multicentre, randomised study of the MAR-Tyn cobalt chromium tin-coated stent in patients with de novo coronary artery lesions: Study design and protocol",
abstract = "Aims: The aim of this randomised study is to evaluate the efficacy and safety of a new bare metal stents (BMS) with thin struts and a novel passive coating as compared to current standard BMS. Methods and results: We designed an international, multicentre, randomised trial planned to include 160 patients assigned to receive either the titanium-nitride coated MAR-tyn stent (International Biomedical Systems, Trieste, Italy) or the Vision stent (Abbott Vascular, Abbott Laboratories, Abbott Park, IL, USA). Patients with left main or bypass graft disease, complex coronary lesions, needing treatment of multiple lesions, with recent myocardial infarction, prior BMS in or within 5 mm of the target lesion, left ventricular ejection fraction ≤25{\%} and at increased bleeding risk are excluded. All patients are treated with dual antiplatelet therapy for two months. The primary endpoint is in-stent late luminal loss (LL) at 6-month follow-up angiography. Secondary endpoints are the incidence of major adverse cardiovascular events (MACE) and stent thrombosis over 12 months after randomisation. Patients' enrolment is open in all centres. Conclusions: This study will address the important question of safety and efficacy of a novel, inert and highly compatible passive coating on a thin-strut BMS with a great potential to be superior to a non-coated widely used BMS.",
keywords = "Cobalt chromium stent, Coronary artery disease, Restenosis, Stent, Study design",
author = "Adnan Kastrati and Marco Balducelli and {Di Sciascio}, Germano and Tiziano Moccetti and Bortone, {Alessandro S.} and Antonio Colombo and Johannes Waltenberger and Christoph Hehrlein",
year = "2010",
month = "4",
doi = "10.4244/EIJV5I8A163",
language = "English",
volume = "5",
pages = "976--980",
journal = "EuroIntervention",
issn = "1774-024X",
publisher = "EuroPCR",
number = "8",

}

TY - JOUR

T1 - A European multicentre, randomised study of the MAR-Tyn cobalt chromium tin-coated stent in patients with de novo coronary artery lesions

T2 - Study design and protocol

AU - Kastrati, Adnan

AU - Balducelli, Marco

AU - Di Sciascio, Germano

AU - Moccetti, Tiziano

AU - Bortone, Alessandro S.

AU - Colombo, Antonio

AU - Waltenberger, Johannes

AU - Hehrlein, Christoph

PY - 2010/4

Y1 - 2010/4

N2 - Aims: The aim of this randomised study is to evaluate the efficacy and safety of a new bare metal stents (BMS) with thin struts and a novel passive coating as compared to current standard BMS. Methods and results: We designed an international, multicentre, randomised trial planned to include 160 patients assigned to receive either the titanium-nitride coated MAR-tyn stent (International Biomedical Systems, Trieste, Italy) or the Vision stent (Abbott Vascular, Abbott Laboratories, Abbott Park, IL, USA). Patients with left main or bypass graft disease, complex coronary lesions, needing treatment of multiple lesions, with recent myocardial infarction, prior BMS in or within 5 mm of the target lesion, left ventricular ejection fraction ≤25% and at increased bleeding risk are excluded. All patients are treated with dual antiplatelet therapy for two months. The primary endpoint is in-stent late luminal loss (LL) at 6-month follow-up angiography. Secondary endpoints are the incidence of major adverse cardiovascular events (MACE) and stent thrombosis over 12 months after randomisation. Patients' enrolment is open in all centres. Conclusions: This study will address the important question of safety and efficacy of a novel, inert and highly compatible passive coating on a thin-strut BMS with a great potential to be superior to a non-coated widely used BMS.

AB - Aims: The aim of this randomised study is to evaluate the efficacy and safety of a new bare metal stents (BMS) with thin struts and a novel passive coating as compared to current standard BMS. Methods and results: We designed an international, multicentre, randomised trial planned to include 160 patients assigned to receive either the titanium-nitride coated MAR-tyn stent (International Biomedical Systems, Trieste, Italy) or the Vision stent (Abbott Vascular, Abbott Laboratories, Abbott Park, IL, USA). Patients with left main or bypass graft disease, complex coronary lesions, needing treatment of multiple lesions, with recent myocardial infarction, prior BMS in or within 5 mm of the target lesion, left ventricular ejection fraction ≤25% and at increased bleeding risk are excluded. All patients are treated with dual antiplatelet therapy for two months. The primary endpoint is in-stent late luminal loss (LL) at 6-month follow-up angiography. Secondary endpoints are the incidence of major adverse cardiovascular events (MACE) and stent thrombosis over 12 months after randomisation. Patients' enrolment is open in all centres. Conclusions: This study will address the important question of safety and efficacy of a novel, inert and highly compatible passive coating on a thin-strut BMS with a great potential to be superior to a non-coated widely used BMS.

KW - Cobalt chromium stent

KW - Coronary artery disease

KW - Restenosis

KW - Stent

KW - Study design

UR - http://www.scopus.com/inward/record.url?scp=77957025430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957025430&partnerID=8YFLogxK

U2 - 10.4244/EIJV5I8A163

DO - 10.4244/EIJV5I8A163

M3 - Article

VL - 5

SP - 976

EP - 980

JO - EuroIntervention

JF - EuroIntervention

SN - 1774-024X

IS - 8

ER -